Why the study?
Clinical use of doxorubicin is hampered by dose-dependent cardiotoxicity leading to heart failure, prompting the need to understand how deregulation of autophagy and senescence contributes to this toxicity.
Design
Review
Authors
Loading...
Highlights evolving DOXO cardiotoxicity mechanisms; leaves open targeted cardioprotective strategies.
Key points are not available for this paper at this time.
Russo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: